europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

2000: Vitamin B2 shifts from chemical synthesis to exclusive biotechnological production in less than 15 years

16/06/2021

Nominated by: DSM, BASF   

Organisation in nomination: DSM, BASF 

Vitamin B2 (riboflavin), is a water-soluble compound, which can be synthesized by plants and microorganisms but not by animals, making it essential for humans and animals to access through their diet. Manufactured riboflavin is used in a variety of applications, including food and feeds, pharmaceuticals and as a food colouring.
For almost five decades, commercial riboflavin was produced almost exclusively by a complex, multi-step chemical synthesis starting from glucose, with low yield at only ~60% and the use of hazardous agents.
However, over the last 15 years, production has shifted towards a single step biotechnological production process, starting from vegetable as carbon sources and using a genetically engineered bacterium (Bacillus subtilis) or fungus (Ashbya gossypii), replacing 50 years of chemical production in just a few years.
Today, almost all vitamin B2 used for human nutrition and health applications as well as in animal feed is now produced biotechnologically, reducing the effect on the environment, compared to the chemical synthesis. Life Cycle analyses demonstrated:
• >70% reduction in fossil raw materials
• >65% reduction in waste water
• ~50% reduction in exhaust emissions
Overall, the ecological fingerprint clearly shows the environmental advantages of biotechnological production. In addition, the products have an excellent safety profile, due to the use of a one-step process and a production microorganism with a long history of safe use, using only renewable raw materials through the entire process.
European companies (primarily BASF and DSM) have led the way to completely transform commercial vitamin B2 production and make it more sustainable, following early industrial development by companies such as Merck.

Image Ashbya gossypii (BASF)

References:

  • Biotechnology of riboflavin, Schwechheimer et al., Appl. Microbiol. Biotechnol. (2016) 100:2107–2119, DOI 10.1007/s00253-015-7256-z
  • Unlocking Nature’s Biosynthetic Power—Metabolic Engineering for the Fermentative Production of Chemicals, Wiley Online Library

 

Back to the list.

Share
Alexandra Simionca
Alexandra Simionca
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member